Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Depreciation and Depletion: 2019-2024

Historic Depreciation and Depletion for Apellis Pharmaceuticals (APLS) over the last 6 years, with Dec 2024 value amounting to $1.8 million.

  • Apellis Pharmaceuticals' Depreciation and Depletion fell 25.82% to $339,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 8.11%. This contributed to the annual value of $1.8 million for FY2024, which is 0.73% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Depreciation and Depletion of $1.8 million as of FY2024, which was up 0.73% from $1.8 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Depreciation and Depletion registered a high of $1.8 million during FY2024, and its lowest value of $637,000 during FY2020.
  • For the 3-year period, Apellis Pharmaceuticals' Depreciation and Depletion averaged around $1.7 million, with its median value being $1.8 million (2023).
  • Data for Apellis Pharmaceuticals' Depreciation and Depletion shows a peak YoY spiked of 165.42% (in 2020) over the last 5 years.
  • Over the past 5 years, Apellis Pharmaceuticals' Depreciation and Depletion (Yearly) stood at $637,000 in 2020, then soared by 116.48% to $1.4 million in 2021, then grew by 12.55% to $1.6 million in 2022, then climbed by 14.95% to $1.8 million in 2023, then increased by 0.73% to $1.8 million in 2024.